Motif Bio is a clinical stage biopharmaceutical company developing novel antibiotics to treat patients with serious and life-threatening infections caused by multi-drug resistant bacteria.
|Motif Bio Announces New Iclaprim Data being Presented at ECCMID 2018|
April 19, 2018
|Posting of UK Annual Report and Accounts & Notice of AGM|
April 17, 2018
|Motif Bio Announces Iclaprim Abstracts for ECCMID 2018 Now Online|
April 11, 2018